- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07880353
Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
Real-World Efficacy and Safety of Sevabertinib as Second-Line or Later-Line Therapy in Patients With HER2-Mutant Advanced Non-Small Cell Lung Cancer: An Observational, Bidirectional Cohort Study
This is a single-center, observational, bidirectional cohort study evaluating the real-world effectiveness, safety, and quality of life associated with sevabertinib in Chinese adults with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy. The study will include both retrospectively identified patients and prospectively enrolled patients. The primary objective is to evaluate real-world progression-free survival. Additional assessments include tumor response, overall survival, safety, and patient-reported quality of life.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Yi XIANG
- Telefonnummer: +86-13816967846
- E-post: xiangyiht@163.com
Studieorter
-
-
Hainan
-
Qionghai, Hainan, Kina, 571400
- Rekrytering
- Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
-
Kontakt:
- Yi XIANG
- Telefonnummer: +86-13816967846
- E-post: xiangyiht@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adult Chinese patients with unresectable locally advanced or metastatic non-squamous NSCLC harboring a documented HER2 (ERBB2) TKD activating mutation who receive sevabertinib as second-line or later-line therapy in routine clinical practice. The study includes both retrospectively identified patients and prospectively enrolled patients.
Beskrivning
Inclusion Criteria:
- Age ≥18 years at the index date.
- Unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
- Documented HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation.
- Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted.
- For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available.
- Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening.
Exclusion Criteria:
- History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD.
- Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance.
- Unstable brain metastases.
- Inability to comply with the study for any reason.
- Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: OTHER
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Sevabertinib-Treated Cohort
Adult Chinese patients with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy in routine clinical practice. Treatment with sevabertinib is determined by the treating physician and is not assigned by the study protocol. |
Sevabertinib is administered as part of routine clinical care, generally at a dose of 20 mg orally twice daily with food until disease progression or unacceptable toxicity, according to the treating physician's clinical judgment. Treatment is not assigned by the study protocol. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Real-World Progression-Free Survival (rwPFS)
Tidsram: From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.
|
rwPFS is defined as the time from the first dose of sevabertinib to the first documented disease progression or death from any cause, whichever occurs first. |
From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Investigator-Assessed Real-World Objective Response Rate (rwORR)
Tidsram: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
rwORR is defined as the proportion of evaluable participants whose best overall response is complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST version 1.1. |
From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
|
Investigator-Assessed Real-World Disease Control Rate (rwDCR)
Tidsram: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
rwDCR is defined as the proportion of evaluable participants who achieve CR, PR, or stable disease (SD). Confirmed and unconfirmed best overall responses will be analyzed separately. |
From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
|
6-Month and 12-Month Progression-Free Survival Rates
Tidsram: At 6 months and 12 months after the first dose of sevabertinib.
|
The probabilities of participants being alive and free from disease progression at 6 months and 12 months after the first dose of sevabertinib. |
At 6 months and 12 months after the first dose of sevabertinib.
|
|
Incidence of Treatment-Related Adverse Events
Tidsram: From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
|
The incidence of treatment-related adverse events of any grade and Grade 3 or higher will be assessed. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. |
From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
|
|
Change From Baseline in EORTC QLQ-C30 Scores
Tidsram: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses cancer-related quality of life. Scores for each scale range from 0 to 100. Higher functional and global health status/quality-of-life scores indicate better functioning or quality of life, whereas higher symptom scores indicate worse symptoms. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
|
Change From Baseline in NSCLC-SAQ Total Score
Tidsram: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) assesses NSCLC-related symptoms. The total score ranges from 0 to 20, with higher scores indicating greater symptom severity. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
|
Change From Baseline in EQ-5D-5L Index Score
Tidsram: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) assesses overall health status across five dimensions. Using the Chinese value set, index scores range from -0.391 to 1.000, with higher scores indicating better health status. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- RWS2026-003
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data (IPD) are not planned to be shared with external researchers because the study uses sensitive clinical data derived from medical records and follow-up. Study data are de-identified and managed under applicable confidentiality, privacy, and institutional data security requirements, with access restricted to authorized study personnel.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .